Alpha1-proteinase inhibitor
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Alpha1-proteinase Inhibitor Deficiency
Conditions
Alpha1-proteinase Inhibitor Deficiency, Emphysema
Trial Timeline
Mar 1, 2006 → Sep 1, 2012
NCT ID
NCT00261833About Alpha1-proteinase inhibitor
Alpha1-proteinase inhibitor is a approved stage product being developed by CSL for Alpha1-proteinase Inhibitor Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00261833. Target conditions include Alpha1-proteinase Inhibitor Deficiency, Emphysema.
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00261833 | Approved | Completed |